Description

Synaptogenix, Inc. operates as a biopharmaceutical entity, actively advancing multiple product candidates through both preclinical and clinical development stages. The company's primary focus involves establishing a therapeutic platform centered on Bryostatin-1, a key drug candidate, primarily for the treatment of Alzheimer's disease. Additionally, Synaptogenix is exploring Bryostatin's potential applications for various other neurodegenerative or cognitive disorders and dysfunctions, including fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease. To facilitate its research and development, Synaptogenix holds licensing agreements with prominent institutions such as Stanford University, the Icahn School of Medicine at Mount Sinai, and The Board of Trustees of the Leland Stanford Junior University. This company was established in 2012 and maintains its corporate headquarters in New York, New York.